

# Surveillance for Babesiosis —

United States, 2014

Annual Summary

**Acknowledgments**

The findings in this U.S. surveillance summary were based, in part, on contributions by state and local health departments.

**Suggested citation**

Centers for Disease Control and Prevention (CDC). Surveillance for Babesiosis — United States, 2014 Annual Summary. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2016.

**Data current as of:**

February 29, 2016

Additional data, updates, or corrections received after that date are not reflected in this summary.

**Summary compiled by:**

Elizabeth B. Gray and Barbara L. Herwaldt

Centers for Disease Control and Prevention

Division of Parasitic Diseases and Malaria

1600 Clifton Road, Mailstop A-06

Atlanta, GA 30329-4027

Telephone: 404-718-4745

E-mail: [parasites@cdc.gov](mailto:parasites@cdc.gov)

Web: <http://www.cdc.gov/parasites/babesiosis/data-statistics/>

## Contents

Main Findings .....	4
Background .....	4
Babesiosis.....	4
Surveillance .....	4
Babesiosis national surveillance case definition (Table 1) .....	6
2014 babesiosis surveillance summary.....	8
Surveillance data, 2011–2014 .....	9
Table 2. Number and incidence of reported cases of babesiosis, by state and year, 2011–2014.....	9
Figure 1. Number of reported cases of babesiosis, by year, 2011–2014 .....	10
Figure 2. Number of reported cases of babesiosis, by county of residence — 31 states, 2014.....	11
Figure 3. Number of reported cases of babesiosis, by age group and year, 2011–2014.....	12
Figure 4. Number of reported cases of babesiosis, by month and year of symptom onset, 2011–2014	13
Figure 5. Hospitalization data for babesiosis case-patients, all years combined, 2011–2014 .....	14
References.....	15
Appendix.....	16

## Main Findings for 2014

- For 2014, CDC was notified of a total of 1,744 U.S. cases of babesiosis, a 1% decrease from the total of 1,761 cases for 2013.
- Babesiosis was a reportable disease in 31 states in 2014 (compared with 27 states in 2013); 22 (71%) of the 31 states notified CDC of at least 1 case.
- Most of the reported cases (94%; n = 1,636/1,744) were in residents of 7 states in the Northeast and upper Midwest (Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin). Tickborne transmission of *Babesia* parasites is well established in these states.

## Background

### Babesiosis

Babesiosis is caused by protozoan parasites of the genus *Babesia*, which infect red blood cells. *Babesia* parasites usually are tickborne but also can be transmitted via blood transfusion or congenitally (1–3).

Most human cases of *Babesia* infection in the United States are caused by the parasite *Babesia microti*. Occasional U.S. cases caused by other species (types) of *Babesia* have been detected (4, 5). *Babesia microti* is spread in nature by *Ixodes scapularis* ticks (also called blacklegged ticks or deer ticks)—primarily in the Northeast and upper Midwest, especially in parts of New England, New York State, New Jersey, Wisconsin, and Minnesota (1, 6–8). The parasite *B. microti* typically is spread by the young nymph stage of the tick, which is found mostly during warm months (spring and summer), in areas with woods, brush, or grass. Infected people might not recall a tick bite because *I. scapularis* nymphs are very small (about the size of a poppy seed).

Many people who are infected with *Babesia microti* are asymptomatic. Some people develop flu-like symptoms, such as fever, chills, sweats, headache, body aches, loss of appetite, nausea, or fatigue. Because *Babesia* parasites infect and destroy red blood cells, babesiosis causes hemolytic anemia, which may range from mild to marked (7).

Babesiosis can be a severe, life-threatening disease (1, 7), particularly in people who:

- do not have a spleen;
- have a weak immune system for other reasons (such as cancer, lymphoma, or AIDS);
- have other serious health conditions (such as liver or kidney disease); or
- are elderly.

### Surveillance

CDC has conducted surveillance for babesiosis in the United States since January 2011, when babesiosis became a nationally notifiable condition. The babesiosis case definition used for surveillance purposes is available online (<http://www.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/>) and is summarized in **Table 1**. Health departments in states where babesiosis is reportable notify CDC of cases that meet the definition via the **National Notifiable Disease Surveillance System (NNDSS)**.

Health departments submit additional information about reported cases using the CDC Case Report Form (CRF) **Babesiosis CRF**  **[PDF, 2 pages, 650 KB]**; data are requested about risk factors for infection, clinical manifestations, and laboratory results. For more information, visit **babesiosis surveillance and case reporting**. Health care providers, laboratories, and the general public should contact their state health department for information about reporting cases of babesiosis.

The number of states in which babesiosis is a reportable condition may change from year to year as additional states begin conducting surveillance. Cases are reported by state and county of residence, which is not necessarily where the exposure occurred. Changes in the number of reported cases do not necessarily represent true changes in disease incidence; ascertainment, reporting, and investigation of cases are subject to clinician awareness and public health agency resources, which may vary from year to year in and among states.

This summary focuses on babesiosis cases reported for surveillance year 2014; some data from previous years (2011–2013) are included to show differences from year to year. Babesiosis surveillance data also are summarized in CDC's [Morbidity and Mortality Weekly Report \(MMWR\)](#) weekly and annual summaries of nationally notifiable diseases. In addition, national surveillance data for 2011 were published previously (8). Because of differences in the timeline for finalizing data in the annual surveillance datasets, data provided in this summary may differ slightly from those previously published. Of note, the year in which a case is counted in national surveillance summaries is assigned by the health department and might reflect the year of symptom onset, diagnosis, or of reporting to or by the health department.

**Table 1. National surveillance case definition for babesiosis\***

Clinical evidence	<p><b>Objective</b> One or more of the following: fever, anemia, or thrombocytopenia.</p> <p><b>Subjective</b> One or more of the following: chills, sweats, headache, myalgia, or arthralgia.</p>
Epidemiologic evidence for transfusion transmission	<p>For the purposes of surveillance, epidemiologic linkage between a transfusion recipient and a blood donor is demonstrated if all of the following criteria are met:</p> <p><b>In the transfusion recipient</b> Received one or more red blood cell (RBC) or platelet transfusions within 1 year before the collection date of a specimen with laboratory evidence of <i>Babesia</i> infection; <b>and</b></p> <p>At least one of these transfused blood components was donated by the donor described below; <b>and</b></p> <p>Transfusion-associated infection is considered at least as plausible as tickborne transmission; <b>and</b></p> <p><b>In the blood donor</b> Donated at least one of the RBC or platelet components that was transfused into the above recipient; <b>and</b></p> <p>The plausibility that this blood component was the source of infection in the recipient is considered equal to or greater than that of blood from other involved donors. (More than one plausible donor can be linked to the same recipient.)</p>
Laboratory criteria for diagnosis	<p><b>Laboratory confirmatory</b> Identification of intraerythrocytic <i>Babesia</i> organisms by light microscopy in a Giemsa, Wright, or Wright-Giemsa–stained blood smear; <b>or</b></p> <p>Detection of <i>Babesia microti</i> DNA in a whole blood specimen by polymerase chain reaction (PCR); <b>or</b></p> <p>Detection of <i>Babesia</i> spp. genomic sequences in a whole blood specimen by nucleic acid amplification; <b>or</b></p> <p>Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation.</p> <p><b>Laboratory supportive</b> Demonstration of a <i>Babesia microti</i> indirect fluorescent antibody (IFA) total immunoglobulin (Ig) or IgG antibody titer of <math>\geq 1:256</math> (or <math>\geq 1:64</math> in epidemiologically linked blood donors or recipients); <b>or</b></p> <p>Demonstration of a <i>Babesia microti</i> immunoblot IgG positive result; <b>or</b></p> <p>Demonstration of a <i>Babesia divergens</i> IFA total Ig or IgG antibody titer of <math>\geq 1:256</math>; <b>or</b></p> <p>Demonstration of a <i>Babesia duncani</i> IFA total Ig or IgG antibody titer of <math>\geq 1:512</math>.</p>

<b>Case classification</b>	
Confirmed	A case that has confirmatory laboratory results and meets at least one of the objective or subjective clinical evidence criteria, regardless of the mode of transmission (can include clinically manifest cases in transfusion recipients or blood donors).
Probable	<p>A case that has supportive laboratory results and meets at least one of the objective clinical evidence criteria (subjective criteria alone are not sufficient); <b>or</b></p> <p>A case that is in a blood donor or recipient epidemiologically linked to a confirmed or probable babesiosis case (as defined above) <b>and</b></p> <p style="padding-left: 40px;">Has confirmatory laboratory evidence but does not meet any objective or subjective clinical evidence criteria; <b>or</b></p> <p style="padding-left: 40px;">Has supportive laboratory evidence and might or might not meet any subjective clinical evidence criteria but does not meet any objective clinical evidence criteria.</p>

\* Available at <http://www.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/>

## 2014 babesiosis surveillance summary

In 2014, babesiosis was a reportable condition in 31 states (compared with 27 states in 2013). CDC was notified of a total of 1,744 cases of babesiosis by 22 (71%) of the 31 states (**Table 2**), a 1% decrease from the total of 1,761 cases for 2013 (**Figure 1**). Among the 22 states that reported at least 1 case of babesiosis for 2014, 94% (n = 1,636/1,744) of the reported cases were in residents of 7 states (Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin). Tickborne transmission of *Babesia* parasites is well established in parts of these states. Differences within and among states in the distributions of reported cases by place of residence are evident in the county-level maps for 2014 (**Figure 2**) and the 3 prior years (2011, 2012, and 2013) in which national surveillance was conducted (**Appendix**). Changes in the number of states conducting surveillance for babesiosis had minimal impact on the fluctuations in the yearly totals of cases. For example, among the 4 states that added babesiosis to their lists of reportable conditions in 2014, Illinois and Ohio each reported only 1 case, and neither Montana nor Utah reported any cases for 2014.

For 2014, the median age of the case-patients was 63 years (range: <1–96 years; n = 1,741). The age distributions for 2014 and the 3 previous years were similar (**Figure 3**), with the largest number of cases reported in persons aged 60–69 years. Similar to the data for previous years, for 2014, among the 1,744 case-patients, 65% (n = 1,131) were male, 35% were female, and the sex was unknown for <1%.

A majority of case-patients have reported getting sick during the spring or summer months (**Figure 4**). Data on month of symptom onset were available for most case-patients (overall, n = 4,268/5,542; 2011, n = 932/1,126; 2012, n = 644/911; 2013, n = 1,352/1,761; 2014, n = 1,340/1,744). The proportion of case-patients with reported symptom onset during June–August has remained fairly consistent from year to year: 81% for 2011 (n = 759/932); 72% for 2012 (n = 464/644); 86% for 2013 (n = 1,156/1,352); and 84% for 2014 (n = 1,124/1,340).

For 2014, among the case-patients for whom data were available, fever was the most frequently reported clinical manifestation (83%; n = 1,258/1,511 patients), followed by chills (69%; n = 815/1,178), thrombocytopenia (69%; n = 546/796), myalgia (68%; n = 819/1,213), and anemia (62%; n = 514/829).

For 2014, hospitalization data were available for 1,500 case-patients, 681 (45%) of whom reportedly had been hospitalized for at least 1 day; the median length of the hospital stay was 3 days (range: 1–35 days) among the 210 case-patients with available data. Overall for 2011–2014, hospitalization data were available for 4,569 case-patients (82% of the total of 5,542), 2,165 of whom (47% of 4,569) reportedly had been hospitalized for at least 1 day (**Figure 5**); the median length of the hospital stay was 4 days (range: 1–39 days) among the 870 case-patients with available data.

For 2014, of the 756 case-patients for whom data were available, 359 (47%) recalled having a tick bite in the 8 weeks before symptom onset. Overall for 2014, 6 cases of babesiosis in blood recipients were classified by the reporting state as transfusion associated.

**Table 2. Number and incidence of reported cases of babesiosis, by state and year, 2011–2014\***

State†	2011		2012		2013		2014	
	No.	Rate‡	No.	Rate	No.	Rate	No.	Rate
Alabama	1	<0.1	0	0.0	0	0.0	1	<0.1
Alaska	—§	—	—	—	—	—	—	—
Arizona	—	—	—	—	—	—	—	—
Arkansas	—	—	—	—	—	—	—	—
California	1	<0.1	4	<0.1	3	<0.1	3	<0.1
Colorado	—	—	—	—	—	—	—	—
Connecticut	74	2.1	123	3.4	268	7.5	205	5.7
Delaware	1	0.1	0	0.0	2	0.2	1	0.1
District of Columbia	—	—	—	—	—	—	—	—
Florida	—	—	—	—	—	—	—	—
Georgia	—	—	—	—	—	—	—	—
Hawaii	—	—	—	—	—	—	—	—
Idaho	—	—	—	—	—	—	—	—
Illinois	—	—	—	—	—	—	1	<0.1
Indiana	0	0.0	1	<0.1	1	<0.1	0	0.0
Iowa	—	—	—	—	—	—	—	—
Kansas	—	—	—	—	—	—	—	—
Kentucky	—	—	—	—	—	—	—	—
Louisiana	—	—	—	—	2	<0.1	0	0.0
Maine	9	0.7	10	0.8	36	2.7	42	3.2
Maryland	4	0.1	3	0.1	9	0.2	2	<0.1
Massachusetts	208	3.1	261	3.9	417	6.2	537	8.0
Michigan	0	0.0	0	0.0	2	<0.1	2	<0.1
Minnesota	73	1.4	41	0.8	64	1.2	49	0.9
Mississippi	—	—	—	—	—	—	—	—
Missouri	—	—	—	—	—	—	—	—
Montana	—	—	—	—	—	—	0	0.0
Nebraska	0	0.0	1	0.1	1	0.1	0	0.0
Nevada	—	—	—	—	—	—	—	—
New Hampshire	13	1.0	19	1.4	22	1.7	42	3.2
New Jersey	166	1.9	92	1.0	171	1.9	159	1.8
New Mexico	—	—	—	—	—	—	—	—
New York	418	2.1	253	1.3	534	2.7	471	2.4
North Carolina	—	—	—	—	—	—	—	—
North Dakota	1	0.1	0	0.0	1	0.1	0	0.0
Ohio	—	—	—	—	—	—	1	<0.1
Oklahoma	—	—	—	—	—	—	—	—
Oregon	1	<0.1	0	0.0	0	0.0	1	<0.1
Pennsylvania	—	—	—	—	—	—	—	—
Rhode Island	73	6.9	56	5.3	142	13.5	172	16.3
South Carolina	—	—	—	—	1	<0.1	3	0.1
South Dakota	—	—	—	—	1	0.1	1	0.1

Tennessee	1	<0.1	0	0.0	0	0.0	0	0.0
Texas	—	—	—	—	1	<0.1	1	<0.1
Utah	—	—	—	—	—	—	0	0.0
Vermont	2	0.3	2	0.3	6	1.0	3	0.5
Virginia	—	—	—	—	—	—	—	—
Washington	0	0.0	0	0.0	1	<0.1	4	0.1
West Virginia	—	—	—	—	0	0.0	0	0.0
Wisconsin	80	1.4	45	0.8	76	1.3	43	0.7
Wyoming	0	0.0	0	0.0	0	0.0	0	0.0
Total¶	1,126	0.8	911	0.6	1,761	1.0	1,744	0.8

\* Year as reported by the health department


† Cases were reported by state of residence, which was not necessarily the state of exposure.

‡ Rate per 100,000 population (9)

§ Not reportable


¶ The denominators for calculations of total incidence rates included only the populations of states in which babesiosis was a reportable condition during the pertinent year.

**Figure 1. Number of reported cases of babesiosis, by year, 2011–2014\***




\* Year as reported by the health department

**Figure 2. Number of reported cases of babesiosis, by county of residence — 31 states, 2014\***




\* N = 1,731; county of residence was known for all but 13 (1%) of the 1,744 total case-patients. See the Appendix for the maps for surveillance years 2011, 2012, and 2013.

**Figure 3. Number of reported cases of babesiosis, by age group and year, 2011–2014\***




\* Data on age were available for most case-patients (2011, n = 1,034/1,126; 2012, n = 785/911; 2013, n = 1,523/1,761; 2014, n = 1,741/1,744).

**Figure 4. Number of reported cases of babesiosis, by month and year of symptom onset, 2011–2014\***



\* Data on month of symptom onset were available for most case-patients (2011, n = 932/1,126; 2012, n = 644/911; 2013, n = 1,352/1,761; 2014, n = 1,340/1,744).

**Figure 5. Hospitalization data for babesiosis case-patients, all years combined, 2011–2014\***


\* Hospitalization data were available for 4,569 case-patients (82% of the total of 5,542 for 2011–2014), 2,165 of whom (47% of 4,569) reportedly had been hospitalized for at least 1 day. The median length of the hospital stay was 4 days (range: 1–39 days) among the 870 case-patients with available data.

## References

1. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med* 2011;155:509–19.
2. Joseph JT, Purtill K, Wong SJ, et al. Vertical transmission of *Babesia microti*, United States. *Emerg Infect Dis* 2012;18:1318–21.
3. Fox LM, Wingerter S, Ahmed A, et al. Neonatal babesiosis: case report and review of the literature. *Pediatr Infect Dis J* 2006;25:169–73.
4. Conrad PA, Kjemtrup AM, Carreno RA, et al. Description of *Babesia duncani* n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. *Int J Parasitol* 2006;36:779–89.
5. Herwaldt BL, de Bruyn G, Pieniazek NJ, et al. *Babesia divergens*-like infection, Washington State. *Emerg Infect Dis* 2004;10:622–9.
6. Herwaldt BL, McGovern PC, Gerwel MP, Easton RM, MacGregor RR. Endemic babesiosis in another eastern state: New Jersey. *Emerg Infect Dis* 2003;9:184–8.
7. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1089–134. Erratum in: *Clin Infect Dis* 2007;45:941.
8. Centers for Disease Control and Prevention. Babesiosis surveillance — 18 states, 2011. *Morb Mortal Wkly Rep* 2012;61:505–9.
9. United States Census Bureau. "Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2015." Available at: <http://www.census.gov/popest/data/state/totals/2015>. Accessed on 17 Feb 2016.


**Appendix. Maps for surveillance years 2011, 2012, and 2013**

**2011: Number of reported cases of babesiosis, by county of residence — 22 states\***




\* N = 1,117; county of residence was known for all but 9 (1%) of the 1,126 total case-patients.

**2012: Number of reported cases of babesiosis, by county of residence — 22 states\***



\* N = 904; county of residence was known for all but 7 (1%) of the 911 total case-patients.

**2013: Number of reported cases of babesiosis, by county of residence — 27 states\***



\* N = 1,749; county of residence was known for all but 12 (1%) of the 1,761 total case-patients.